Illumina Inc (NASDAQ:ILMN)

CAPS Rating: 4 out of 5

The Company is a developer, manufacturer and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function.

Results 1 - 20 of 113 : 1 2 3 4 5 6 Next »

Recs

1
Member Avatar optioncoach (97.40) Submitted: 1/31/2015 6:14:47 PM : Outperform Start Price: $195.37 ILMN Score: -5.26

This is a very interesting play on development of mapping of the genetic code. Predictive medicine based on your genetic make-up is very interesting. I think this is a big thing to help people in the future. I would be a couple grand to know what I have the highest probably of getting and work to improve my chances of not getting it or monitoring for whatever it is. I really think this is interesting and I think they are getting to a price point that makes sense and can be useful to us all. Also, on Friday they did some stuff in DC that is leading the way in this very field. I think this is a must own and must own category.

Recs

0
Member Avatar NickInvestments (71.68) Submitted: 1/30/2015 6:41:41 PM : Outperform Start Price: $195.37 ILMN Score: -5.26

Genetic reading and writing are massive future markets.

Recs

0
Member Avatar mrudolph72 (60.45) Submitted: 1/10/2015 4:56:14 PM : Outperform Start Price: $195.92 ILMN Score: -3.29

2015 Nasdaq Dozen

Recs

0
Member Avatar kirk802 (< 20) Submitted: 12/28/2014 6:22:18 PM : Outperform Start Price: $188.20 ILMN Score: +2.69

Outputs from Illumina's sequencing machines and reagants are the rocket fuel for the arrival of precision medicine treatments for cancer and other diseases. For cancer patients and the related industries, consistency is demanded by the FDA and so is imperative - not optional. Therefore, Illumina will remain the state of the art for many years, with a secure overall market position. And, over the next few years, its outputs will become the de facto standard around which apps will be created. Think of outputs from Illumina as like the DOS that formed the basis of Microsoft. Already, companies like Foundation Medicine and others depend on Illumina to provide the tools to sequence cancer genes and provide recommendations for treatments that are saving lives. Read up about Foundation Medicine (FMI), and then think about what that means for Illumina.

Recs

0
Member Avatar RW (55.00) Submitted: 12/15/2014 2:43:51 PM : Outperform Start Price: $180.01 ILMN Score: +3.27

I like what Illumina stands for so I'm willing to put my money on the line.

Recs

0
Member Avatar lwwjrmd (75.86) Submitted: 12/15/2014 10:45:33 AM : Outperform Start Price: $181.62 ILMN Score: +2.91

GENOME

Recs

0
Member Avatar My535 (45.42) Submitted: 11/28/2014 12:12:09 PM : Outperform Start Price: $189.04 ILMN Score: +1.86

Early mover in genetic testing technology.

Recs

0
Member Avatar Tophinater (45.33) Submitted: 11/21/2014 10:38:53 AM : Outperform Start Price: $187.63 ILMN Score: +2.49

I like the name of the company.

Recs

0
Member Avatar pmarty59 (35.14) Submitted: 11/12/2014 1:13:09 PM : Outperform Start Price: $178.98 ILMN Score: +6.04

Leader in genetic modeling for everyone. Unlimited demand over next decade.

Recs

0
Member Avatar almodovar (< 20) Submitted: 9/29/2014 1:17:06 PM : Outperform Start Price: $165.28 ILMN Score: +11.47

dna

Recs

0
Member Avatar BeverlyB7 (81.06) Submitted: 8/21/2014 3:32:46 PM : Outperform Start Price: $171.74 ILMN Score: +8.26

It has partnered with major pharmaceuticals to upgrade sequencing
to potentially identify Cancer!

Recs

2
Member Avatar TMFInnovator (68.40) Submitted: 8/21/2014 10:14:01 AM : Outperform Start Price: $174.15 ILMN Score: +6.48

I always thought of Illumina as more of an academic company, more interested in progressing the field of research in personalized medicine than ever being very commercially-focused.

Until today.

http://finance.yahoo.com/news/illumina-announces-strategic-partnerships-astrazeneca-060000336.html

New partnerships with AstraZeneca, Janssen Biotech, Inc., and Sanofi show that the drug-makers (who hold the purse-strings in the industry) value Illumina's genomic sequencing technology to help them make more efficient cancer-fighting drugs.

I'm a true believer that this will be a huge wave of the future. I'll be watching for how new drugs from these companies progress through the FDA trials.

Exciting industry to be a part of right now. Outperform, for 5+ years.

Recs

0
Member Avatar nrynn (22.73) Submitted: 7/14/2014 5:20:15 PM : Outperform Start Price: $176.84 ILMN Score: +4.10

Strong demand in personalized medicine.
Leader and almost monopolistic grip in the market.
Lot of cash reserves.
Good track record of delivering.

Recs

4
Member Avatar unkownuser (97.02) Submitted: 7/13/2014 4:58:01 PM : Underperform Start Price: $178.99 ILMN Score: -2.60

Illumina's ceo, Jay Flatley, is a criminal plain and simple. He lacks creativity and ingenuity, and makes up for it by literally stealing the intellectual property of other companies. Flatley even outlined his strategy to boldly ignore patent rights by asserting that it would take years for these things to wind their way through the court system. Illumina lost patent litigation big time with Syntrix most recently (Illumina was pirating Syntrix' IP). But Flatley has still not learned that stealing is bad; and in fact he has found a way to compound his thievery. He bought (overpaid would be more accurate) the failing pre-natal dianostics firm Verinata Health and brought it under the Illumina umbrella. This was an odd move since Verinata was not only pirating the technology used for their prenatal test, but they were pirating it from Sequenom (Nasdaq: SQNM) one of Illumina's biggest customers! Can you say faux pas? Actually, faux pas is a bit of an understatement, back-stabbing, short-sighted, and criminal would be a bit more appropriate. So now Flatley is pirating through acquisition, AND alienating his largest customer in the process, BRILLIANT! For their part, Sequenom is now looking at alternative providers and will soon distance themselves from the criminal enterprise and underhanded offerings of Jay Flatley and Illumina. How long can a business model like Illumina's last? If they steal from their own customers, why wouldn't they steal from their own shareholders too... I wonder who's validating their numbers and how trustworthy they are.

Recs

0
Member Avatar umight (49.54) Submitted: 7/6/2014 10:48:10 AM : Outperform Start Price: $182.56 ILMN Score: +0.58

I thought Google's IPO price, around $80 - $90 as I recall, was outrageous. There was no way I could justify that kind of P/E ratio. Silly me.

It seems to me that Illumina's situation is strikingly similar. The current price is outrageous. The P/E ratio is unjustifiable. But just as Google was way ahead of the pack in search technology, so is Illumina way ahead of the pack in sequencing.

I am not going to be silly this time.

Recs

0
Member Avatar NHWeston102 (65.67) Submitted: 6/24/2014 2:07:31 PM : Outperform Start Price: $171.92 ILMN Score: +6.09

Top-dog at sequencing, they have a deep moat which leaves competitors to fight over crumbs in the biotech analytics community. Since they serve a large number of firms, their contacts might also make them not only a buy-out candidate but target of a bidding war among several suitors. A good situation all the way around!

Recs

0
Member Avatar Vanapple (< 20) Submitted: 6/9/2014 10:27:21 AM : Outperform Start Price: $170.73 ILMN Score: +6.80

Stock is roaring up again for another good run. One of few biotechs comming back into favour. I would watch this over weeks to months.

Recs

0
Member Avatar PuddinHead42 (42.18) Submitted: 5/28/2014 11:02:36 PM : Outperform Start Price: $158.99 ILMN Score: +13.12

Showing strong accumulation on the right side of the base.

Recs

0
Member Avatar hba24 (95.73) Submitted: 5/28/2014 10:19:05 AM : Outperform Start Price: $156.93 ILMN Score: +14.42

Genomic revolution play.

Recs

0
Member Avatar SmoothHughes (87.77) Submitted: 5/21/2014 3:29:41 PM : Outperform Start Price: $154.57 ILMN Score: +15.02

Inexpensive gene sequencing will transform medicine; it'll just take longer than most think it will, hence the 5+ year pick of this industry leader.

Results 1 - 20 of 113 : 1 2 3 4 5 6 Next »

Featured Broker Partners


Advertisement